SAN ANTONIO, June 3, 2011 /PRNewswire/ -- At the 2011 SNM Annual Meeting in San Antonio, Siemens Healthcare (booth #6033) will address the increasing demand for molecular imaging procedures and Siemens' efforts to expand molecular imaging's availability in three directions: patient access, clinical utilization, and new clinical applications. Through this benchmark-redefining growth of molecular imaging, Siemens (NYSE: SI) is "Expanding Your Return on Innovation."
Expanded Clinical Utilization
Two of the most challenging issues facing physicians who are expanding their clinical utilization of molecular imaging scanners are the dual mandates to improve patient safety and increase productivity. Siemens is meeting both of these core needs through its commitment to minimizing dose while maximizing speed. Siemens offers innovative solutions where the lowest dose can be used, while still scanning patients faster than ever.
Symbia® IQ-SPECT technology, which recently received the 2011 North American Nuclear Cardiology Product Differentiation Excellence of the Year Award from the business research and consulting firm of Frost & Sullivan, enables routine scans using half dose and double speed. Its proven technologies provide a comprehensive cardio workup, while easing the burden of the global molybdenum shortage via a reduction in technetium dose. Diagnostic SPECT-CT, including calcium scoring, uses half of the typical technetium dose and cuts acquisition time from approximately 20 minutes to less than five minutes with the addition of IQ-SPECT.
With technologies such as TrueV and ultraHD-PET, where the axial field of view is increased by 33%, and 2mm uniform resolution across the entire field of view is achieved, along with two times improvement in signal to